Description
ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 ( TrxR1 ) with IC 50 s of 50 nM and 3.0 µM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.Appearance:SolidIC50& Target:IC50: 50 nM (IDO1), 3.0 µM (TrxR1)In Vitro:ZC0109 (24 h) inhibits cancer cells with IC 50 s of 3.44 µM (HCT-116), 12.4 µM (CT26), and 10.2 µM (HeLa), respectively. ZC0109 (2.5-10 µM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells. ZC0109 (2.5-10 µM; 24 h) induces apoptosis andIn Vivo:ZC0109 (15, 30, and 60mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice. ZC0109 (60mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanteBiological Activity:ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 ( TrxR1 ) with IC 50 s of 50 nM and 3.0 µM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis